Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24077532 | 0.88 | ALDH1A1 (0.53) | MAPK1HSD17B10RAB9APOLBALDH1A1 | |
| SCHEMBL15057284 | 0.87 | HPGD (0.48) | MAPK1RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL4490577 | 0.87 | AKR1C3 (0.60) | CASRRAB9APOLBALDH1A1NPC1 | |
| SCHEMBL134016 | 0.87 | EGFR (0.57) | EGFRMAPK1HSD17B10RAB9APOLB | |
| SCHEMBL4485291 | 0.86 | PARP14 (0.47) | MEN1KMT2AAKR1C3 | |
| SCHEMBL11088028 | 0.85 | AKR1C3 (0.47) | CASRRAB9AALDH1A1MAPTAKR1C3 | |
| SCHEMBL7438829 | 0.82 | ALDH1A1 (0.57) | RAB9APOLBALDH1A1NPC1HPGD | |
| SCHEMBL20798155 | 0.82 | FPR3 (0.48) | MAPK1RAB9AALDH1A1NPC1HPGD | |
| SCHEMBL25203341 | 0.82 | PTPRC (0.57) | CASRMAPK1HSD17B10RAB9AALDH1A1 | |
| SCHEMBL9133529 | 0.82 | MTNR1A (0.55) | MAPK1RAB9AALDH1A1NPC1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055040-A1 | Synthesis Of Benzodiazepine Derivatives | TRIO MEDICINES LIMITED (GB) | 2023-02-23 | — | — | US | disclosed |
| US-11447454-B2 | Synthesis of benzodiazepine derivatives | TRIO MEDICINES LIMITED (GB) | 2022-09-20 | — | — | US | disclosed |
| WO-2022182845-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-09-01 | — | — | WO | disclosed |
| EP-3331865-B1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | TRIO MEDICINES LTD (GB) | 2021-05-12 | — | — | EP | disclosed |
| US-20200223807-A1 | Synthesis Of Benzodiazepine Derivatives | TRIO MEDICINES LIMITED (GB) | 2020-07-16 | — | — | US | disclosed |
| US-10570102-B2 | Synthesis of benzodiazepine derivatives | TRIO MEDICINES LIMITED (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20180237400-A1 | Synthesis Of Benzodiazepine Derivatives | TRIO MEDICINES LIMITED (GB) | 2018-08-23 | — | — | US | disclosed |
| EP-3331865-A1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | Trio Medicines Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| CN-108055843-A | Synthesis of benzodiazepine derivatives | 特里奥医药有限公司 | 2018-05-18 | — | — | CN | disclosed |
| WO-2017025727-A1 | SYNTHESIS OF BENZODIAZEPINE DERIVATIVES | TRIO MEDICINES LIMITED (GB) | 2017-02-16 | — | — | WO | disclosed |
| EP-0384636-A1 | Pharmaceutically active compounds | FISONS plc (GB) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200223807-A1 | Synthesis Of Benzodiazepine Derivatives | GABRA1, GABRA5, GABRE | CASR 2454/4885EGFR 2212/4885MAPK1 2292/4885 |
| US-11447454-B2 | Synthesis of benzodiazepine derivatives | GABRA1, GABRA5, GABRE | CASR 2454/4885EGFR 2212/4885MAPK1 2292/4885 |
| US-20180237400-A1 | Synthesis Of Benzodiazepine Derivatives | GABRE, GABRA1, GABRA5 | CASR 2438/4885EGFR 1950/4885MAPK1 2409/4885 |
| US-10570102-B2 | Synthesis of benzodiazepine derivatives | GABRE, GABRA1, GABRA5 | CASR 2438/4885EGFR 1950/4885MAPK1 2409/4885 |
| US-20230055040-A1 | Synthesis Of Benzodiazepine Derivatives | GABRE, GABRA1, GABRA5 | CASR 2438/4885EGFR 1950/4885MAPK1 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.